# Patient-Trial Match Report

*Generated: 2026-01-05 06:59:11*

## Patient Profile

- **Age**: 72
- **Sex**: Male
- **Cancer Type**: prostate cancer
- **Biomarkers**: BRCA2 germline mutation

**Clinical Description**:
> 72-year-old male with metastatic castration-resistant prostate cancer (mCRPC), germline BRCA2 mutation confirmed. Disease progression on enzalutamide and subsequent docetaxel. Olaparib initiated with good PSA response (decline from 145 to 32) lasting 11 months, now PSA rising (72). Bone-predominant disease with multiple skeletal metastases, currently on denosumab. No visceral involvement. Seeking combination approaches with PARP inhibitors or novel agents for DNA repair deficient tumors. Good functional status despite bone disease. No bone pain requiring opioids.

- **Location Preference**: United States

## Search Summary

- **Search terms used**: 11
- **Total trials evaluated**: 100
- **Excluded by fast filter**: 17
- **LLM scored**: 83

## üü¢ HIGH Likelihood (28 trials)

### [NCT02861573](https://clinicaltrials.gov/study/NCT02861573)

**Phase Ib/II Trial of Pembrolizumab (MK-3475) Combination Therapies in Metastatic Castration-Resistant Prostate Cancer (mCRPC) (KEYNOTE-365)**

- **Sponsor**: Merck Sharp & Dohme LLC
- **Phase**: Phase 1/Phase 2
- **Status**: Recruiting
- **Confidence**: 85%

**‚úì Supporting Factors:**
- Histologically confirmed adenocarcinoma of the prostate
- ECOG status of 1
- Age 72

**Assessment:**
> The patient's cancer type matches the trial's indication for metastatic castration-resistant prostate cancer. Treatment line matches as the trial is for previously treated patients, and the patient has undergone appropriate treatments. The patient's ECOG status is acceptable for the trial.

---

### [NCT03972657](https://clinicaltrials.gov/study/NCT03972657)

**A Phase 1/2 Study of REGN5678 (Anti-PSMAxCD28) With or Without Cemiplimab (Anti-PD-1) in Patients With Metastatic Castration-Resistant Prostate Cancer and Other Tumors Associated With PSMA Expression**

- **Sponsor**: Regeneron Pharmaceuticals
- **Phase**: Phase 1/Phase 2
- **Status**: Recruiting
- **Confidence**: 85%

**‚úì Supporting Factors:**
- Metastatic castration-resistant prostate cancer (mCRPC) confirmed by clinical details
- Prior therapies include enzalutamide, which is a required second-generation anti-androgen therapy
- PSA value increase after previous treatments meets eligibility criteria

**Assessment:**
> The patient's cancer type matches the trial's indication (mCRPC). The patient has prior systemic therapies, including a second-generation anti-androgen therapy, and meets the minimum PSA requirement. There are no conflicts or uncertainties based on the provided data.

---

### [NCT04038502](https://clinicaltrials.gov/study/NCT04038502)

**An Open-label, Multicenter Phase II Study to Compare the Efficacy of Carboplatin as First-line Followed by Second-line Olaparib Versus Olaparib as First-line Followed by Second-line Carboplatin in the Treatment of Patients With Castration Resistant Prostate Cancer Containing Homologous Recombination Deficiency**

- **Sponsor**: VA Office of Research and Development
- **Phase**: Phase 2
- **Status**: Recruiting
- **Confidence**: 85%

**‚úì Supporting Factors:**
- Diagnosis of prostate cancer
- mCRPC as evidenced by PSA level of 72 after prior therapy
- Prior therapy includes enzalutamide
- ECOG Performance Status of 1
- Germline BRCA2 mutation confirmed

**? Uncertainties:**
- Normal organ and bone marrow function labs (e.g., hemoglobin, ANC, platelet count, liver function tests, creatinine clearance) are not provided

**Assessment:**
> The patient has metastatic castration-resistant prostate cancer (mCRPC) which matches the trial's indication. The patient's age and treatment history fit within the inclusion criteria, and they are on ongoing gonadal androgen deprivation therapy. There are some uncertainties related to the necessary organ function tests, but overall, the patient is likely to meet the eligibility requirements.

---

### [NCT04071236](https://clinicaltrials.gov/study/NCT04071236)

**A Phase I and Randomized Phase II Trial of Radium-223 Dichloride, M3814, &Amp; Avelumab in Advanced Metastatic Castrate-Resistant Prostate Cancer (mCRPC)**

- **Sponsor**: National Cancer Institute (NCI)
- **Phase**: Phase 1/Phase 2
- **Status**: Recruiting
- **Confidence**: 85%

**‚úì Supporting Factors:**
- ECOG status is 1
- Progressive castration-resistant prostate cancer with multiple skeletal metastases
- Prior treatments include enzalutamide and docetaxel
- Patient has a baseline PSA level of 72 ng/mL with evidence of progressively increasing PSA values
- Patient is in the age range of 18+
- Patient is currently on denosumab, which is a bone health agent

**? Uncertainties:**
- Albumin level
- Hemoglobin level
- Leukocyte count
- Absolute neutrophil count
- Platelet count
- Total bilirubin level
- AST/ALT levels
- Creatinine level or GFR

**Assessment:**
> The patient's cancer type, prostate cancer, aligns with the trial's focus on metastatic castration-resistant prostate cancer (mCRPC). The patient has received prior treatments as required by the trial. While there are some uncertainties regarding organ function lab values, the critical criteria have been met, suggesting high likelihood of eligibility.

---

### [NCT04337580](https://clinicaltrials.gov/study/NCT04337580)

**A Phase II Trial of FASN Inhibition by Omeprazole in Combination With Cabazitaxel in Patients With Docetaxel- and Castration-Resistant Prostate Cancer**

- **Sponsor**: Wake Forest University Health Sciences
- **Phase**: Phase 2
- **Status**: Recruiting
- **Confidence**: 85%

**‚úì Supporting Factors:**
- The patient has metastatic castration-resistant prostate cancer (mCRPC), which matches the trial condition of castration-resistant prostate cancer.
- The patient has a history of prior taxane treatment (docetaxel) in the castration-refractory setting.
- The patient is 72 years old, fitting the age criterion of 18 or older.
- The patient's ECOG status is 1, which is acceptable per trial criteria.

**? Uncertainties:**
- Organ function lab values are not provided to confirm absolute neutrophil count, platelets, total bilirubin, AST/ALT, and creatinine levels.

**Assessment:**
> The patient's cancer type (mCRPC) directly matches the trial's focus on castration-resistant prostate cancer. The patient has received prior treatment with docetaxel, which aligns with the inclusion criteria for prior taxane treatment. The patient's age and ECOG status meet the trial requirements. However, there is an uncertainty regarding organ function, which slightly lowers confidence.

---

### [NCT05125016](https://clinicaltrials.gov/study/NCT05125016)

**Phase 1/2 Study of REGN4336 (a PSMAxCD3 Bispecific Antibody) Administered Alone or in Combination With Cemiplimab or REGN5678 (a PSMAxCD28 Bispecific Antibody) in Patients With Metastatic Castration-Resistant Prostate Cancer**

- **Sponsor**: Regeneron Pharmaceuticals
- **Phase**: Phase 1/Phase 2
- **Status**: Recruiting
- **Confidence**: 85%

**‚úì Supporting Factors:**
- Confirmed metastatic castration-resistant prostate cancer (mCRPC)
- Prior treatment with enzalutamide (a second-generation anti-androgen therapy)
- PSA value is rising (currently PSA = 72, which is above the eligibility threshold of ‚â•4 ng/mL)
- ECOG status is 1, indicating good functional status

**Assessment:**
> The patient's cancer type matches the trial's indication of metastatic castration-resistant prostate cancer. The patient has undergone multiple lines of prior therapy, satisfying the treatment line criteria. There are no conflicts or uncertainties making the patient ineligible.

---

### [NCT05766371](https://clinicaltrials.gov/study/NCT05766371)

**A Phase 2 Study of Pembrolizumab Plus 177Lu-PSMA-617 in Patients With Metastatic Castration Resistant Prostate Cancer**

- **Sponsor**: University of California, San Francisco
- **Phase**: Phase 2
- **Status**: Recruiting
- **Confidence**: 85%

**‚úì Supporting Factors:**
- Patient has metastatic castration-resistant prostate cancer (mCRPC), which matches the trial conditions.
- Patient is male, 72 years old, meeting the age requirement.
- Patient has a confirmed progression on enzalutamide, which is a second generation androgen signaling inhibitor.
- Patient has an ECOG status of 1, meeting the performance status requirement.

**? Uncertainties:**
- Organ function labs (e.g., renal and hepatic function markers) are not provided in the patient profile.

**Assessment:**
> The patient has metastatic castration-resistant prostate cancer and has previously progressed on enzalutamide, making him eligible based on disease and treatment line criteria. There are no critical conflicts identified, and while organ function details are missing, they do not inherently disqualify the patient.

---

### [NCT06457919](https://clinicaltrials.gov/study/NCT06457919)

**A Phase 1b/2 Study Evaluating the Activity of Tinengotinib (TT-00420) in Combination With Androgen Receptor Signaling Inhibitors (ARSIs) in Patients With Metastatic Castration Resistant Prostate Cancer (mCRPC)**

- **Sponsor**: Memorial Sloan Kettering Cancer Center
- **Phase**: Phase 1/Phase 2
- **Status**: Recruiting
- **Confidence**: 85%

**‚úì Supporting Factors:**
- Age: 72
- Sex: male
- Cancer type: prostate cancer
- Biomarkers: BRCA2 germline mutation
- ECOG status: 1
- Progressive disease on enzalutamide: PSA progression with rising PSA levels
- Bone-predominant metastatic disease with no visceral involvement
- Currently on enzalutamide
- Good functional status despite bone disease, no bone pain requiring opioids

**? Uncertainties:**
- Organ function lab values (not provided)
- Current serum PSA level (not confirmed whether it meets the threshold of 2.0 ng/mL or above)

**Assessment:**
> The patient has metastatic castration-resistant prostate cancer, which aligns with the trial focus. The treatment history shows progression on enzalutamide, fulfilling the eligibility conditions. There are no significant conflicts, merely uncertainties regarding organ function and specific PSA level.

---

### [NCT06470243](https://clinicaltrials.gov/study/NCT06470243)

**A Phase III Study of Cabazitaxel With or Without Carboplatin in Patients With Metastatic Castrate-Resistant Prostate Cancer (mCRPC), Stratified by Aggressive Variant Signature**

- **Sponsor**: SWOG Cancer Research Network
- **Phase**: Phase 3
- **Status**: Recruiting
- **Confidence**: 85%

**‚úì Supporting Factors:**
- Histologically confirmed diagnosis of prostate cancer
- Castrate-resistant prostate cancer
- Metastatic disease by bone scan
- Prior treatment included docetaxel
- Age is 72 years
- ECOG status is 1
- No brain metastases

**? Uncertainties:**
- Requirement for biopsy tissue submission for alteration assessment
- Testing for AVPC-Molecular Pathologic Signature
- Availability of biopsy tissue that meets the specified criteria
- Need for blood test results related to organ function

**Assessment:**
> The patient's cancer type matches the indication being studied in the trial, as they have metastatic castrate-resistant prostate cancer. The patient has received appropriate prior treatments, including docetaxel, confirming their eligibility as a previously treated patient. The supporting factors indicate alignment with the trial's criteria, although there are uncertainties regarding tissue submission and lab results that could affect final eligibility.

---

### [NCT06533644](https://clinicaltrials.gov/study/NCT06533644)

**A Phase 2a Multicenter, Dose-Escalation and Dose Optimization Study of SYNC-T Therapy SV-102 for Patients With Metastatic Castration-Resistant Prostate Cancer (mCRPC)**

- **Sponsor**: Syncromune, Inc.
- **Phase**: Phase 2
- **Status**: Recruiting
- **Confidence**: 85%

**‚úì Supporting Factors:**
- Patient has metastatic castration-resistant prostate cancer (mCRPC)
- ECOG status is 1
- Patient has progressed after receiving multiple prior therapies including enzalutamide and docetaxel
- Patient has not received more than three prior lines of therapy
- Patient has no brain metastases
- Patient is male and over 18 years old
- Patient can provide informed consent

**? Uncertainties:**
- Serum testosterone levels before screening not provided
- Bone marrow, renal, and hepatic function not explicitly confirmed
- Need confirmation that patient can undergo anesthesia or sedation
- Need confirmation that patient agrees to provide tumor tissue and undergo on-treatment tumor biopsy

**Assessment:**
> The patient's condition is confirmed to match the study's focus on metastatic castration-resistant prostate cancer. The treatment line is appropriate, as the patient has received prior treatments qualifying them for this study, and meets the necessary criteria such as age and ECOG status. However, there are several uncertainties regarding specific organ function checks and procedural agreements that need verification.

---

### [NCT06764485](https://clinicaltrials.gov/study/NCT06764485)

**A Phase 3, Two-part, Randomized, Open-label, Adaptive Study Comparing BMS-986365 Versus Investigator's Choice of Therapy Comprising Either Docetaxel or Second Androgen Receptor Pathway Inhibitor (ARPI), in Participants With Metastatic Castration-resistant Prostate Cancer (mCRPC) - rechARge**

- **Sponsor**: Celgene
- **Phase**: Phase 3
- **Status**: Recruiting
- **Confidence**: 85%

**‚úì Supporting Factors:**
- Confirmed metastatic castration-resistant prostate cancer (mCRPC) diagnosis
- Prior treatment with enzalutamide (an androgen receptor pathway inhibitor)
- ECOG status 1 indicating good functional status
- No brain metastases

**Assessment:**
> The patient's prostate cancer diagnosis matches the study's focus on mCRPC. The patient has received prior treatment with an androgen receptor pathway inhibitor (enzalutamide) and does not have any brain metastases, satisfying critical eligibility criteria. The patient is also symptomatic but has an acceptable ECOG status. Therefore, the patient likely qualifies for the trial.

---

### [NCT06609005](https://clinicaltrials.gov/study/NCT06609005)

**A Phase 1 and Phase 2, Multi-Center, Open-Label Study to Evaluate the Safety, Pharmacokinetics, Pharmacodynamics, and Preliminary Evidence of Antitumor Activity of INV-9956 in Adult Patients With Advanced Metastatic Castration Resistant Prostate Cancer**

- **Sponsor**: Shenzhen Ionova Life Sciences Co., Ltd.
- **Phase**: Phase 1/Phase 2
- **Status**: Recruiting
- **Confidence**: 85%

**‚úì Supporting Factors:**
- Male aged 72 years
- Histologically confirmed adenocarcinoma of the prostate (prostate cancer)
- Castration resistant prostate cancer (mCRPC)
- Metastatic disease with multiple skeletal metastases
- Received at least one prior line of taxane-based chemotherapy (docetaxel)
- Received at least one line of hormonal AR targeted therapy (enzalutamide)
- ECOG performance status 1
- No brain metastases
- Currently on androgen deprivation therapy (denosumab) for bone disease
- Life expectancy greater than 3 months

**? Uncertainties:**
- Adequate marrow, liver, and kidney function (not specified in the profile)
- INR ‚â§1.5 (not specified in the profile)
- Ability to swallow study treatment (not specified in the profile)

**Assessment:**
> The patient's diagnosis of metastatic castration-resistant prostate cancer and prior treatments align with the trial's focus. He meets most inclusion criteria and has no evidence of exclusion criteria based on the provided information. Minor uncertainties regarding organ function and some specifics remain.

---

### [NCT06691984](https://clinicaltrials.gov/study/NCT06691984)

**A Phase 3, Open-label, Multicenter, Randomized Study of Xaluritamig vs Cabazitaxel or Second Androgen Receptor-Directed Therapy in Subjects With Metastatic Castration-Resistant Prostate Cancer Previously Treated With Chemotherapy**

- **Sponsor**: Amgen
- **Phase**: Phase 3
- **Status**: Recruiting
- **Confidence**: 85%

**‚úì Supporting Factors:**
- Patient has metastatic castration-resistant prostate cancer (mCRPC).
- Patient is male, 72 years old, meeting age criteria.
- ECOG status of 1 is acceptable.
- Patient has had prior treatment with enzalutamide and docetaxel.
- Prior treatment with PARP inhibitor (olaparib) is allowed.
- No central nervous system metastases.

**? Uncertainties:**
- Adequate organ function is not explicitly confirmed.

**Assessment:**
> The patient's cancer diagnosis matches the trial's indication for metastatic castration-resistant prostate cancer. The patient has received prior treatments required for eligibility and has a suitable ECOG status, leading to a high likelihood of eligibility.

---

### [NCT06785636](https://clinicaltrials.gov/study/NCT06785636)

**A Phase 1b/2a, MultiCenter, Open- Label Study of Pocenbrodib as Monotherapy or in Combination With Abiraterone Acetate, Olaparib, or 177Lu-PSMA-617 in Participants With Metastatic Castration-Resistant Prostate Cancer (mCRPC)**

- **Sponsor**: Pathos AI, Inc.
- **Phase**: Phase 1/Phase 2
- **Status**: Recruiting
- **Confidence**: 85%

**‚úì Supporting Factors:**
- Patient is male with documented prostate adenocarcinoma (prostate cancer)
- Patient is 72 years old (‚â•18 years of age)
- Patient has metastatic disease (metastatic castration-resistant prostate cancer)
- ECOG status is 1
- No brain metastases reported
- Patient has previously received olaparib, which is listed in trial for combination therapy

**? Uncertainties:**
- Most recent prostate biopsy results are not explicitly confirmed (no evidence of small cell or neuroendocrine histology)
- Prior intervention details (timing and type) beyond olaparib and denosumab are not provided

**Assessment:**
> The patient has metastatic prostate cancer matching the trial's indication. They are above 18 years old, have an acceptable ECOG status, and do not have brain metastases. While the patient has prior therapies, the trial allows for previously treated patients. The only uncertainties lie in confirming the histology and timing of prior treatments, but these do not fundamentally exclude the patient.

---

### [NCT06800313](https://clinicaltrials.gov/study/NCT06800313)

**Phase 1/2 Study of HLD-0915 in Patients With Metastatic Castration Resistant Prostate Cancer (mCRPC)**

- **Sponsor**: Halda Therapeutics OpCo, Inc.
- **Phase**: Phase 1/Phase 2
- **Status**: Recruiting
- **Confidence**: 85%

**‚úì Supporting Factors:**
- Age is 72, which meets the age requirement.
- ECOG status is 1, which is within the acceptable range (0-1).
- Has confirmed metastatic castration-resistant prostate cancer (mCRPC) with prior progression on systemic therapies.
- No brain metastases.
- Currently on a stable bisphosphonate (denosumab) regimen.
- Has prior treatment history consistent with the trial's requirement for previously treated patients.

**? Uncertainties:**
- Adequate hematological, renal, and hepatic function is not provided.
- No details provided regarding the patient's ability to swallow oral medication.

**Assessment:**
> The patient's prostate cancer type matches the trial's indication, he has previously been treated which aligns with the trial's requirement. There are a couple of uncertainties regarding organ function and the ability to swallow medications, but overall, he meets the critical eligibility criteria.

---

### [NCT04995198](https://clinicaltrials.gov/study/NCT04995198)

**PROMISE Registry: A Prostate Cancer Registry of Outcomes and Germline Mutations for Improved Survival and Treatment Effectiveness**

- **Sponsor**: Prostate Cancer Clinical Trials Consortium
- **Phase**: N/A
- **Status**: Recruiting
- **Confidence**: 85%

**‚úì Supporting Factors:**
- Patient has prostate cancer.
- Patient lives in the United States.
- Patient has a BRCA2 germline mutation.

**Assessment:**
> The patient's cancer type matches the trial's condition, and the patient resides in the United States. The inclusion criteria are satisfied with the confirmed prostate cancer diagnosis and necessary biomarker. There are no specified exclusions that apply to the patient.

---

### [NCT04898634](https://clinicaltrials.gov/study/NCT04898634)

**A Phase 1 Study of JNJ-78278343, a T-Cell-Redirecting Agent Targeting Human Kallikrein 2 (KLK2), for Advanced Prostate Cancer**

- **Sponsor**: Janssen Research & Development, LLC
- **Phase**: Phase 1
- **Status**: Recruiting
- **Confidence**: 85%

**‚úì Supporting Factors:**
- Confirmed adenocarcinoma of the prostate which has spread to other body parts
- Prior treatment with at least 1 prior novel androgen receptor (AR)-targeted therapy (enzalutamide)
- ECOG performance status of 1

**? Uncertainties:**
- Concurrent use of any other anticancer treatment must be discontinued for at least 2 weeks before the first dose of study drug (patient is currently on denosumab)
- Organ function status is not provided

**Assessment:**
> The patient's prostate cancer matches the trial's focus on advanced prostate cancer. He has previously been treated with enzalutamide, fulfilling the treatment line requirement. His ECOG status is acceptable. The main uncertainty relates to the need for discontinuation of current therapies.

---

### [NCT05519449](https://clinicaltrials.gov/study/NCT05519449)

**A Phase 1, Open-Label, Multicenter Study of JANX007 in Subjects With Metastatic Castration-Resistant Prostate Cancer**

- **Sponsor**: Janux Therapeutics
- **Phase**: Phase 1
- **Status**: Recruiting
- **Confidence**: 85%

**‚úì Supporting Factors:**
- Male, aged 72
- Histologically confirmed metastatic castration-resistant prostate cancer (mCRPC)
- Progressed on enzalutamide and docetaxel
- Received olaparib as PARP inhibitor
- ECOG status of 1
- No brain metastases

**? Uncertainties:**
- Organ function status is not provided.

**Assessment:**
> The patient's cancer type matches the trial's indication for metastatic castration-resistant prostate cancer. He has had the required prior therapies and meets the age and ECOG criteria. The main uncertainty lies in the organ function status, but since he has a good functional status otherwise, this is not a significant barrier to eligibility.

---

### [NCT06193486](https://clinicaltrials.gov/study/NCT06193486)

**A Phase I Clinical Trial of an Infusion of Autologous Gamma Delta T Cells Genetically Engineered With a Chimeric Receptor to Target the Prostate Stem Cell Antigen in Patients With Metastatic Castration Resistant Prostate Cancer**

- **Sponsor**: H. Lee Moffitt Cancer Center and Research Institute
- **Phase**: Phase 1
- **Status**: Recruiting
- **Confidence**: 85%

**‚úì Supporting Factors:**
- Patient has metastatic castration-resistant prostate cancer (mCRPC), matching the trial conditions studied.
- Patient has progressed through standard of care treatments, including prior therapies of enzalutamide and docetaxel.
- Patient is eligible based on ECOG status of 1.
- Patient has adequate organ function as confirmed by good functional status.
- Patient's life expectancy is at least 6 months.

**‚úó Potential Conflicts:**
- Patient is currently on denosumab instead of zoledronic acid, which requires changing to zoledronic acid before lymphodepletion chemotherapy.

**Assessment:**
> The patient's cancer type matches the trial's focus on mCRPC, and the patient has undergone the necessary prior treatments, indicating alignment with trial requirements. The main conflict is related to the use of denosumab instead of zoledronic acid, which is needed per the eligibility criteria. However, all other criteria appear to be met, leading to a high confidence in eligibility.

---

### [NCT06801236](https://clinicaltrials.gov/study/NCT06801236)

**A Phase 1 Study to Assess the Safety, Pharmacokinetics, Pharmacodynamics, and Preliminary Efficacy of ACE-232 in Patients With Metastatic Castration-Resistant Prostate Cancer (CRPC)**

- **Sponsor**: Acerand Therapeutics (Hong Kong) Limited
- **Phase**: Phase 1
- **Status**: Recruiting
- **Confidence**: 85%

**‚úì Supporting Factors:**
- Metastatic Castration-resistant Prostate Cancer (mCRPC)
- ECOG status of 1
- Good functional status despite bone disease
- No brain metastases
- Prior treatments include enzalutamide and docetaxel

**? Uncertainties:**
- Organ function status is not explicitly provided

**Assessment:**
> The patient's cancer type matches the trial's indication for metastatic castration-resistant prostate cancer (mCRPC). The patient is previously treated, which aligns with the trial requirements as it is intended for patients who are difficult to treat or intolerant to standard treatment. ECOG status is acceptable, and there are no contraindicating factors such as brain metastases. Minor uncertainty exists regarding organ function, but overall confidence is high.

---

### [NCT06826768](https://clinicaltrials.gov/study/NCT06826768)

**A Phase Ib Clinical Trial to Optimize Risk Benefit of REGN5678 (PSMAxCD28 Bispecific Antibody) Plus Cemiplimab (Anti-PD-1 Monoclonal Antibody) in Patients With Metastatic Castration-resistant Prostate Cancer**

- **Sponsor**: M.D. Anderson Cancer Center
- **Phase**: Phase 1
- **Status**: Recruiting
- **Confidence**: 85%

**‚úì Supporting Factors:**
- Age: 72
- Sex: male
- Cancer type: metastatic castration-resistant prostate cancer (mCRPC)
- ECOG performance status: 1
- Prior therapies: enzalutamide, docetaxel, olaparib (more than two lines of systemic therapy including anti-androgen treatment)
- No brain metastases

**? Uncertainties:**
- Eligibility for urinary or blood tests to confirm organ function (e.g., hemoglobin, absolute neutrophil count, platelet count, liver function tests, etc.)

**Assessment:**
> The patient has metastatic castration-resistant prostate cancer, matching the trial's focus. He has been previously treated with multiple therapies, which aligns with the treatment line requirement of having disease progression after at least two lines of systemic therapy. The ECOG status is acceptable, and there are no issues regarding brain metastases. Some organ function criteria need confirmation through testing, but overall the patient likely qualifies.

---

### [NCT06236139](https://clinicaltrials.gov/study/NCT06236139)

**Phase 1/2 Dose-Escalation and Cohort Study of STEAP1 CART With Enzalutamide in Participants With mCRPC**

- **Sponsor**: Fred Hutchinson Cancer Center
- **Phase**: Phase 1/Phase 2
- **Status**: Recruiting
- **Confidence**: 85%

**‚úì Supporting Factors:**
- Patient has metastatic castration-resistant prostate cancer (mCRPC)
- Patient has a BRCA2 germline mutation
- Patient is 72 years old
- Patient has an ECOG status of 1
- Patient has progressed on at least two prior therapies, including enzalutamide and docetaxel

**? Uncertainties:**
- Serum creatinine level
- Total bilirubin level
- AST and ALT levels
- ANC, hemoglobin, and platelet counts

**Assessment:**
> The patient's diagnosis of mCRPC aligns with the trial's conditions studied. The patient has received multiple prior treatments and has a BRCA2 mutation, which supports potential eligibility for the trial targeting DNA repair deficient tumors. All key eligibility criteria regarding disease type and treatment history are met. Some organ function values are not available, which introduces some uncertainty.

---

### [NCT04890613](https://clinicaltrials.gov/study/NCT04890613)

**Phase Ib Expansion Study of CX-5461 in Patients With Solid Tumours and BRCA2 and/or PALB2 Mutation**

- **Sponsor**: Senhwa Biosciences, Inc.
- **Phase**: Phase 1
- **Status**: Recruiting
- **Confidence**: 85%

**‚úì Supporting Factors:**
- Patient has metastatic castration-resistant prostate cancer (mCRPC) which matches the trial's cancer type.
- Patient has documented evidence of germline BRCA2 mutation.
- Patient's ECOG status is 1, which is within the acceptable range.

**? Uncertainties:**
- No specific laboratory results for organ function were provided; thus, eligibility based on bone marrow, hepatic, and renal function cannot be fully confirmed.

**Assessment:**
> The patient's prostate cancer type aligns with the trial's inclusion criteria, they have a confirmed BRCA2 mutation, and their ECOG status is acceptable. Although organ function lab results are not available, there are no explicit conflicts with the primary eligibility criteria.

---

### [NCT06177171](https://clinicaltrials.gov/study/NCT06177171)

**A Phase I/Ib Study of Olaparib and ASTX727 in BRCA1/2- and HRD-mutated Tumors**

- **Sponsor**: Pamela Munster
- **Phase**: Phase 1
- **Status**: Recruiting
- **Confidence**: 85%

**‚úì Supporting Factors:**
- Patient has metastatic castration-resistant prostate cancer (mCRPC), which aligns with the advanced solid tumor criteria.
- Patient presents with a germline BRCA2 mutation, which is required for eligibility.
- ECOG status is 1, which is acceptable for the trial.
- Patient's age is 72, which meets the age requirement of 18+.
- No brain metastases, aligning with eligibility criteria.
- Patient has received prior therapies, including a PARP inhibitor (olaparib), which is permissible as per criteria.

**? Uncertainties:**
- No specific lab values provided to assess adequate organ function (bone marrow, hepatic function, and kidney function).

**Assessment:**
> The patient's cancer type, treatment history, and biomarkers align well with the trial's eligibility criteria. The main uncertainty lies in the assessment of organ function due to missing lab values.

---

### [NCT06492122](https://clinicaltrials.gov/study/NCT06492122)

**A Phase 1, First-in-Human, Open-label Study Evaluating the Safety, Tolerability, Pharmacokinetics, and Efficacy of [225Ac]Ac-FL-020 in Participants With mCRPC.**

- **Sponsor**: Full-Life Technologies GmbH
- **Phase**: Phase 1
- **Status**: Recruiting
- **Confidence**: 85%

**‚úì Supporting Factors:**
- Age ‚â• 18 years
- ECOG performance status of 1
- Histologically or cytologically confirmed metastatic CRPC
- Documented progression of the disease based on investigator's judgment
- Have previously been treated with an androgen receptor signaling inhibitor (enzalutamide)
- Have previously been treated with a taxane regimen (docetaxel)
- Bone-predominant disease without visceral involvement
- Patient has continued primary androgen deprivation with denosumab
- Life expectancy > 3 months
- No brain metastases

**? Uncertainties:**
- Castrate serum testosterone level is unknown
- Organ function values are not provided

**Assessment:**
> The patient has metastatic castration-resistant prostate cancer, which matches the trial's indication. They are previously treated with required therapies such as enzalutamide and docetaxel. All major inclusion criteria are met, although some organ function and testosterone levels are not specified.

---

### [NCT06582017](https://clinicaltrials.gov/study/NCT06582017)

**A First-in-human Phase 1a/1b Study to Evaluate Safety and Tolerability of QXL138AM in Patients With Locally Advanced Un-resectable and/or Metastatic Solid Tumors and Multiple Myeloma**

- **Sponsor**: Nammi Therapeutics Inc
- **Phase**: Phase 1
- **Status**: Recruiting
- **Confidence**: 85%

**‚úì Supporting Factors:**
- Patient has metastatic castration-resistant prostate cancer (mCRPC), an included condition.
- Patient has an ECOG performance status of 1.
- Patient is 72 years old, which is above the minimum age requirement of 18.
- Patient has a history of disease progression despite prior therapies, including enzalutamide and docetaxel.

**Assessment:**
> The patient's cancer type, metastatic castration-resistant prostate cancer, matches the trial's inclusion of prostate cancer. The patient has progressed on standard therapies, aligning with the trial's criteria for previously treated patients. ECOG status and age are acceptable, confirming a high likelihood of eligibility.

---

### [NCT06659614](https://clinicaltrials.gov/study/NCT06659614)

**Prostate Tissue Biobank for People at Genetic Risk for Aggressive Disease**

- **Sponsor**: Abramson Cancer Center at Penn Medicine
- **Phase**: N/A
- **Status**: Recruiting
- **Confidence**: 85%

**‚úì Supporting Factors:**
- Confirmed pathogenic variant: BRCA2 germline mutation
- Age: 72
- ECOG status: 1
- No brain metastases

**Assessment:**
> The patient's cancer type is metastatic prostate cancer, which matches the trial's focus on prostate cancer and genetic predisposition. The patient is confirmed to have a BRCA2 mutation, meeting the biomarker requirement. Furthermore, the patient is not treatment-naive, but the trial eligibility does not exclude previously treated patients, leading to a determination of matching criteria overall.

---

### [NCT04662580](https://clinicaltrials.gov/study/NCT04662580)

**A Phase 1, Multicenter, Open-Label, Dose-Escalation, and Dose-Expansion Study to Evaluate the Safety, Pharmacokinetics, and Anti-Tumor Activity of ARX517 as Monotherapy and in Combination With Androgen Receptor Pathway Inhibitors in Subjects With Metastatic Prostate Cancer**

- **Sponsor**: Janssen Research & Development, LLC
- **Phase**: Phase 1
- **Status**: Recruiting
- **Confidence**: 70%

**‚úì Supporting Factors:**
- Patient is male and 72 years old, which meets age criteria (‚â•18 years)
- Patient has histologically confirmed prostate adenocarcinoma (prostate cancer)
- Patient has documented evidence of disease progression on prior therapies (enzalutamide, docetaxel, olaparib)
- Patient's ECOG status is 1, which is acceptable
- No brain metastases noted
- Patient has a BRCA2 germline mutation, indicating a DNA repair deficiency, aligning with the interest in combination approaches for such tumors

**‚úó Potential Conflicts:**
- Patient has received enzalutamide, which is excluded for combination cohorts

**? Uncertainties:**
- Adequate blood counts not provided in patient profile
- PSMA positivity not explicitly confirmed in patient profile

**Assessment:**
> The patient's cancer type matches the trial's target as they have metastatic prostate cancer. They also meet the age and ECOG status criteria. However, they have previously received enzalutamide, which is a significant conflict with the eligibility criteria for this trial. While there are uncertainties regarding blood counts and PSMA positivity, the overall likelihood of match reflects that they meet mostly relevant criteria despite the conflict.

---

## üü° MEDIUM Likelihood (2 trials)

### [NCT04706663](https://clinicaltrials.gov/study/NCT04706663)

**A Multi-Center Natural History Study of Precision-Based Genomics in Prostate Cancer**

- **Sponsor**: National Cancer Institute (NCI)
- **Phase**: N/A
- **Status**: Recruiting
- **Confidence**: 65%

**‚úì Supporting Factors:**
- Histologically confirmed prostate cancer
- Germline BRCA2 mutation
- ECOG status is 1 (acceptable for trials)
- Age is 72 (above 18)

**? Uncertainties:**
- Lack of specific information on the presence of required gene mutations (PIK3, AKT, etc.) in addition to BRCA2
- Unclear if the patient qualifies as an exceptional responder based solely on past therapy outcomes

**Assessment:**
> The patient's cancer type matches the trial's indication, and he meets the age and ECOG status criteria. However, there are uncertainties related to the required biomarker specifications and whether his past response qualifies him as an exceptional responder.

---

### [NCT01441089](https://clinicaltrials.gov/study/NCT01441089)

**Collection of Blood From Therapeutic Trial Participants for Analysis of Genetic Differences in Drug Disposition and Pharmacokinetics of Probe Medications**

- **Sponsor**: National Cancer Institute (NCI)
- **Phase**: N/A
- **Status**: Recruiting
- **Confidence**: 65%

**‚úì Supporting Factors:**
- Age >= 3 years old
- ECOG status of 1

**‚úó Potential Conflicts:**
- Patient has previously been treated with systemic therapies, while trial information does not specify whether previously treated patients are eligible.

**? Uncertainties:**
- Trial requires participants to be enrolled in an NIH intramural research program which is not confirmed in the patient profile.
- Unclear if the patient‚Äôs treatment classifies as 'current treatment' as specified in trial.

**Assessment:**
> The patient's cancer type of prostate cancer matches the trial's conditions studied. The patient is also above the minimum age requirement and has a manageable ECOG status. However, the trial does not clarify if it accepts previously treated patients, raising doubts about eligibility. The requirement for NIH intramural program enrollment also introduces uncertainty.

---

## Excluded (69 trials)

### Excluded by Fast Filter

| NCT ID | Reason |
|--------|--------|
| [NCT06398639](https://clinicaltrials.gov/study/NCT06398639) | Patient age 72 is above maximum age 69 |
| [NCT04090567](https://clinicaltrials.gov/study/NCT04090567) | Trial requires female patients |
| [NCT04315324](https://clinicaltrials.gov/study/NCT04315324) | Low relevance score (0.00) - trial doesn't appear to target patient's condition/biomarkers |
| [NCT05434234](https://clinicaltrials.gov/study/NCT05434234) | Low relevance score (0.00) - trial doesn't appear to target patient's condition/biomarkers |
| [NCT05929768](https://clinicaltrials.gov/study/NCT05929768) | Low relevance score (0.00) - trial doesn't appear to target patient's condition/biomarkers |
| [NCT06545955](https://clinicaltrials.gov/study/NCT06545955) | Low relevance score (0.00) - trial doesn't appear to target patient's condition/biomarkers |
| [NCT06907043](https://clinicaltrials.gov/study/NCT06907043) | Low relevance score (0.00) - trial doesn't appear to target patient's condition/biomarkers |
| [NCT02333604](https://clinicaltrials.gov/study/NCT02333604) | Low relevance score (0.00) - trial doesn't appear to target patient's condition/biomarkers |
| [NCT03568630](https://clinicaltrials.gov/study/NCT03568630) | Low relevance score (0.00) - trial doesn't appear to target patient's condition/biomarkers |
| [NCT04373564](https://clinicaltrials.gov/study/NCT04373564) | Patient age 72 is above maximum age 64 |
| [NCT04970056](https://clinicaltrials.gov/study/NCT04970056) | Low relevance score (0.00) - trial doesn't appear to target patient's condition/biomarkers |
| [NCT05587439](https://clinicaltrials.gov/study/NCT05587439) | Low relevance score (0.00) - trial doesn't appear to target patient's condition/biomarkers |
| [NCT05625529](https://clinicaltrials.gov/study/NCT05625529) | Low relevance score (0.00) - trial doesn't appear to target patient's condition/biomarkers |
| [NCT05761782](https://clinicaltrials.gov/study/NCT05761782) | Low relevance score (0.00) - trial doesn't appear to target patient's condition/biomarkers |
| [NCT06151223](https://clinicaltrials.gov/study/NCT06151223) | Low relevance score (0.00) - trial doesn't appear to target patient's condition/biomarkers |
| [NCT06242470](https://clinicaltrials.gov/study/NCT06242470) | Low relevance score (0.00) - trial doesn't appear to target patient's condition/biomarkers |
| [NCT06710379](https://clinicaltrials.gov/study/NCT06710379) | Low relevance score (0.00) - trial doesn't appear to target patient's condition/biomarkers |

### Excluded by Eligibility Assessment

| NCT ID | Sponsor | Reason |
|--------|---------|--------|
| [NCT03574571](https://clinicaltrials.gov/study/NCT03574571) | Memorial Sloan Kette | The patient has received systemic therapy (enzalutamide, docetaxel, olaparib) which does not align with the trial's previous treatment requirement. |
| [NCT04104893](https://clinicaltrials.gov/study/NCT04104893) | VA Office of Researc | Patient is not eligible based on required biomarkers; the trial requires dMMR or CDK12-/- but does not specify acceptance of BRCA2 mutation. |
| [NCT05168618](https://clinicaltrials.gov/study/NCT05168618) | University of Utah | Trial requires non-measurable disease outside the pelvis, patient has bone-predominant disease which may not fit as non-measurable under RECIST 1.1. |
| [NCT05422911](https://clinicaltrials.gov/study/NCT05422911) | James J. Peters Vete | Patient has prior treatment with enzalutamide and docetaxel, while trial requires patients who have not received abiraterone acetate, enzalutamide, or apalutamide. |
| [NCT05820724](https://clinicaltrials.gov/study/NCT05820724) | VA Greater Los Angel | Trial focuses on prostate cancer diagnosis via imaging, whereas the patient has metastatic castration-resistant prostate cancer (mCRPC) which requires treatment, not diagnostic evaluation. |
| [NCT05873192](https://clinicaltrials.gov/study/NCT05873192) | M.D. Anderson Cancer | Patient has prior chemotherapy (docetaxel and olaparib) which conflicts with Exclusion Criteria 3: Patients who have had prior chemotherapy are excluded. |
| [NCT05849298](https://clinicaltrials.gov/study/NCT05849298) | Novartis Pharmaceuti | Patient has prior therapy with enzalutamide and docetaxel, which disqualifies them from the trial that excludes prior therapy with second generation anti-androgens. |
| [NCT06100705](https://clinicaltrials.gov/study/NCT06100705) | Yale University | Prior treatment with three FDA-approved androgen/AR signaling inhibitors (enzalutamide, docetaxel, olaparib) |
| [NCT06136650](https://clinicaltrials.gov/study/NCT06136650) | Merck Sharp & Dohme  | Patient has received prior systemic therapy (enzalutamide, docetaxel, olaparib) while trial requires that participants must have progressed on or after treatment with one next-generation hormonal agent (NHA). |
| [NCT06145633](https://clinicaltrials.gov/study/NCT06145633) | Fred Hutchinson Canc | PSMA SUVmean requirement is not met; specific PSMA level for eligibility not provided. |
| [NCT06004661](https://clinicaltrials.gov/study/NCT06004661) | Novartis Pharmaceuti | Patient is past treatment - has progressed on enzalutamide and docetaxel, which indicates he's previously treated, while the trial might be targeting treatment-naive patients. |
| [NCT06574880](https://clinicaltrials.gov/study/NCT06574880) | Angela Y. Jia, MD Ph | Trial studies locally advanced prostate cancer, patient has metastatic castration-resistant prostate cancer (mCRPC) |
| [NCT06568562](https://clinicaltrials.gov/study/NCT06568562) | University of Utah | Patient has advanced metastatic castration-resistant prostate cancer (mCRPC), while the trial specifies progression after treatment with 177Lu-PSMA-617, which the patient has not received. |
| [NCT06629779](https://clinicaltrials.gov/study/NCT06629779) | Pfizer | Patient has previously been treated with enzalutamide, violating the treatment-naive requirement. |
| [NCT06632977](https://clinicaltrials.gov/study/NCT06632977) | Alliance for Clinica | Prior treatment with enzalutamide, docetaxel, and olaparib indicates patient is not treatment-naive, while the trial requires progressive mCRPC but does not state it is for previously treated patients specifically. |
| [NCT03492424](https://clinicaltrials.gov/study/NCT03492424) | Weill Medical Colleg | Patient has clinically-evident metastatic disease, which is excluded by trial criteria. |
| [NCT04254133](https://clinicaltrials.gov/study/NCT04254133) | Fred Hutchinson Canc | Patient is a resident of the United States but not Washington state, which is required for this trial. |
| [NCT04729114](https://clinicaltrials.gov/study/NCT04729114) | Astellas Pharma Glob | The patient has received prior ARPI treatment with enzalutamide (not ARPI-na√Øve as required by the trial for certain cohorts). |
| [NCT05129605](https://clinicaltrials.gov/study/NCT05129605) | Massachusetts Genera | Patient has a prior diagnosis of prostate cancer and has been treated, whereas the trial excludes individuals with prior diagnosis or treatment of prostate cancer. |
| [NCT05411354](https://clinicaltrials.gov/study/NCT05411354) | Power Life Sciences  | Patient has a prior therapy history which may exclude them if the trial is for treatment-naive patients. |
| ... | ... | *and 32 more* |

## Search Terms Used

| Term | Source | Confidence |
|------|--------|------------|
| BRCA2 germline mutation | manual | 1.0 |
| prostate cancer | manual | 1.0 |
| BRCA2 germline mutation prostate cancer | manual | 1.0 |
| BRCA2 germline mutation mCRPC | llm | 0.9 |
| germline BRCA2 mutation prostate cancer | llm | 0.9 |
| mCRPC | llm | 0.8 |
| metastatic castration-resistant prostate cancer | llm | 0.8 |
| BRCA2 mutation | llm | 0.9 |
| BRCA2mutation | llm | 0.8 |
| BRCA2-mutation | llm | 0.8 |
| germline BRCA2 mutation | llm | 0.9 |

## Information That Would Improve Matches

The following patient data was not provided but would help refine eligibility assessment:

- **Organ function labs** (hematology, liver, renal) - required by all interventional trials
- **Cardiac status/QTc interval** - relevant for trials with cardiotoxicity risk
